Mouse Anti-VEGFA Recombinant Antibody (clone mAb G6-31)

Customer Review

There are currently no Customer reviews or questions for HPAB-0330CQ. Click the button above to contact us or submit your feedback about this product.

Q&As

1. Is the anti-VEGFA recombinant antibody clone MAB G6-31 suitable for use in Western blotting?

   A: Yes, the anti-VEGFA recombinant antibody clone MAB G6-31 (HPAB-0330CQ) is suitable for use in Western blotting. It provides specific binding to VEGFA, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-VEGFA recombinant antibody clone MAB G6-31?

   A: The recommended storage condition for the anti-VEGFA recombinant antibody clone MAB G6-31 (HPAB-0330CQ) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-VEGFA recombinant antibody clone MAB G6-31 be used in immunoprecipitation assays?

   A: Yes, the anti-VEGFA recombinant antibody clone MAB G6-31 (HPAB-0330CQ) can be used in immunoprecipitation assays. It provides specific binding to VEGFA, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-VEGFA recombinant antibody clone MAB G6-31 effective in ELISA applications?

   A: Yes, the anti-VEGFA recombinant antibody clone MAB G6-31 (HPAB-0330CQ) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of VEGFA.

5. What is the optimal dilution for using the anti-VEGFA recombinant antibody clone MAB G6-31 in immunofluorescence?

   A: The optimal dilution for using the anti-VEGFA recombinant antibody clone MAB G6-31 (HPAB-0330CQ) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Shen, Jingjing, et al. "Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment." Science advances 9.4 (2023): eabq3104. https://doi.org/10.1126/sciadv.abq3104
   This study focuses on developing an innovative delivery system for macromolecular ophthalmic drugs to treat ocular fundus diseases using eyedrop formulations. Traditional treatments like intravitreal injections present risks such as infections and retinal detachment. This research introduces a penetrating carrier based on fluorocarbon-modified chitosan (FCS), which can self-assemble with proteins to form nanocomplexes. These nanocomplexes effectively traverse ocular barriers to reach the posterior eye segments, demonstrating superior therapeutic responses in mouse models of choroidal melanoma and choroidal neovascularization compared to conventional methods. The FCS/anti-PDL1 and FCS/anti-VEGFA eyedrops induced stronger antitumor immune responses and inhibited vascular proliferation, respectively, showcasing the potential for at-home treatment of various eye diseases.
   In this study, Creative Biolabs provided crucial therapeutic antibodies that were integral to the research. Specifically, they supplied anti-VEGFA (Cat#: HPAB-0330CQ), which was used in the formulation of FCS/anti-VEGFA nanocomplexes for treating choroidal neovascularization. This antibody played a pivotal role in achieving comparable therapeutic effects to intravitreal injections, thus validating the efficacy of the new delivery system. The contributions of Creative Biolabs significantly advanced the study, highlighting the potential for noninvasive, effective treatment options for ocular diseases.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# HPAB-0330CQ, RRID: AB_3111386)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "Clone mAb G6-31"

See other products for "VEGFA"

Select a product category from the dropdown menu below to view related products.

Humanized Antibodies Immunotoxins IgG Antibodies Fab Antibodies Human Antibodies Mouse Antibodies Chicken IgY Antibodies Neutralizing Antibodies Blocking Antibodies Rabbit Monoclonal Antibodies IgM Antibodies ADCC Enhanced Antibodies ScFv Antibodies Single Domain Antibodies Antibody Magnetic Beads NHP Antibodies ScFv-Fc Chimeras IHC Kits & Antibodies Extracellular Vesicle Antibodies Biparatopic Antibodies